Welcome to our dedicated page for BridgeBio Oncology Therapeutics SEC filings (Ticker: BBOT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BridgeBio Oncology Therapeutics, Inc. filings document the regulatory record of a Nasdaq-listed clinical-stage biopharmaceutical company developing small-molecule oncology programs for RAS and PI3Kα malignancies. Its 8-K reports cover material events such as leadership and board changes, compensatory arrangements, clinical-data press releases, and operating or financial results.
Proxy materials describe annual meeting matters, director elections, board classification, auditor ratification, and governance practices. The company’s filings also identify its common stock capital structure and formal disclosure categories for clinical and regulatory updates, governance, compensation, and public-company reporting obligations.
BridgeBio Oncology Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 16, 2026. Investors will elect two Class I directors, Frank McCormick and Peter Lebowitz, to three-year terms and ratify Deloitte & Touche LLP as auditor for 2026.
The meeting will be held online via webcast, with only stockholders of record as of April 20, 2026, entitled to vote. There were 80,112,725 shares of common stock outstanding on that date, each with one vote. The company uses “notice and access” for proxy materials.
BBOT remains an emerging growth and smaller reporting company and uses scaled executive compensation disclosure. Its board is staggered into three classes, which can make rapid changes of control more difficult. The proxy details director and executive biographies, committee structures, director compensation, and fees paid to Deloitte & Touche LLP and prior auditor Withum.
BridgeBio Oncology Therapeutics, Inc. filed Prospectus Supplement No. 5 registering 63,054,549 shares of Common Stock for resale by the selling securityholders. The supplement incorporates a Form 8-K reporting leadership changes: Pedro Beltran, Ph.D. was appointed President and Chief Executive Officer and joined the Board; Idan Elmelech was appointed Chief Operating Officer and named principal financial officer; Uneek Mehra will depart as CFO with last day April 30, 2026, and Marc Cobo was named principal accounting officer. The supplement references an attached press release and existing executive indemnification and severance plan exhibits.
BridgeBio Oncology Therapeutics, Inc. announced a broad leadership transition. Pedro Beltran, Ph.D., formerly Chief Scientific Officer, has been appointed President, Chief Executive Officer and Class III director, succeeding Eli Wallace, Ph.D., who resigned from the Board and will remain as an advisor.
The Board also promoted Idan Elmelech to Chief Operating Officer and named him principal financial officer, while appointing Marc Cobo as principal accounting officer following the planned departure of CFO Uneek Mehra. In addition, Neil Kumar, Ph.D., was appointed Executive Chairman as the company advances three clinical assets in RAS- and PI3Kα-driven cancers.
BridgeBio Oncology Therapeutics, Inc. director Peter F. Lebowitz received a grant of stock options covering 63,350 shares of common stock. The options have an exercise price of $8.72 per share and expire on March 23, 2036.
According to the vesting terms, 1/36th of the options vest in substantially equal monthly installments on each monthly anniversary of March 24, 2026, so long as he continues to provide service to the company. Following this grant, he holds 63,350 derivative securities directly.
BridgeBio Oncology Therapeutics, Inc. director Peter F. Lebowitz has filed an initial insider ownership report on Form 3. This filing establishes his status as a director of the company under insider reporting rules. The provided data show no reported transactions or derivative positions in this filing excerpt.
BridgeBio Oncology Therapeutics, Inc. registers 63,054,549 shares of Common Stock for resale by selling securityholders under a prospectus supplement dated March 26, 2026. The supplement amends the Form S-1 prospectus dated September 10, 2025 and attaches a Form 8-K reporting a board appointment.
The prospectus supplement states the resale is by selling securityholders (not an issuer primary sale); the company will not receive proceeds from these resales. The attached Form 8-K discloses the appointment of Peter Lebowitz, M.D., Ph.D. to the Board and a one-time option grant of 63,350 shares at an exercise price of $8.72 per share.
BridgeBio Oncology Therapeutics, Inc. reported that its board expanded to nine directors and appointed Peter Lebowitz, M.D., Ph.D. as a Class I director effective March 24, 2026. His term runs until the 2026 annual stockholders meeting and he will serve on the nominating and governance and compensation committees.
The board determined Dr. Lebowitz is independent under Nasdaq and applicable regulations and disclosed no related-party arrangements or transactions requiring Regulation S-K Item 404(a) disclosure. As a non-employee director, he will receive standard board compensation, including a one-time stock option for 63,350 common shares at an exercise price of $8.72 per share, matching the Nasdaq Global Market closing price on March 24, 2026. He also entered into the company’s standard indemnification agreement covering certain expenses and liabilities arising from his board service.
BridgeBio Oncology Therapeutics, Inc. reported that Chief Financial Officer Uneek Mehra received new equity awards. On March 10, 2026, he was granted stock options covering 105,000 shares of common stock at an exercise price of $10.19 per share, expiring on March 9, 2036.
The option vests in substantially equal monthly installments, with 1/48 of the shares vesting each month from January 1, 2026, contingent on continued service. He also received 23,330 restricted stock units, each representing one share of common stock, vesting in 16 equal quarterly installments over four years from January 1, 2026, and settling in shares upon vesting.
BridgeBio Oncology Therapeutics, Inc. Chief Scientific Officer Pedro Beltran received new equity awards as part of his compensation. He was granted an option for 210,000 shares of common stock at an exercise price of 10.19 per share, vesting in substantially equal monthly installments from January 1, 2026.
He also received 46,670 restricted stock units, each representing one share of common stock. These RSUs vest in 16 equal quarterly installments over four years from January 1, 2026, and are settled in shares upon vesting, subject to his continued service.